Breast Cancer Clinical Trials in Nashville, Tennessee

40 studies are recruiting for breast cancer in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

   This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   17 in total

   Run by

   LigaChem Biosciences, Inc.

   See if you can join NCT06774963 on ClinicalTrials.gov

2. A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

   The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute (Nashville), Nashville, Tennessee

   Locations

   53 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT07102381 on ClinicalTrials.gov

3. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Nashville, Nashville, Tennessee

   Locations

   25 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

4. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   96 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

5. A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

   The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic ER+, HER2- breast cancer. The study consists of 2 phases: P…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee

   Locations

   77 in total

   Run by

   Genentech, Inc.

   See if you can join NCT07100106 on ClinicalTrials.gov

6. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

   The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute - Pharmacy, Nashville, Tennessee

   Locations

   433 in total

   Run by

   Pfizer

   See if you can join NCT07062965 on ClinicalTrials.gov

7. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

   This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   6 in total

   Run by

   ModeX Therapeutics, An OPKO Health Company

   See if you can join NCT06239194 on ClinicalTrials.gov

8. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   26 in total

   Run by

   SystImmune Inc.

   See if you can join NCT06293898 on ClinicalTrials.gov

9. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

   This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-p…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   242 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT06790693 on ClinicalTrials.gov

10. A Study of PHST001 in Advanced Solid Tumors

    This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advan…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville, Tennessee

    Locations

    20 in total

    Run by

    Pheast Therapeutics

    See if you can join NCT06840886 on ClinicalTrials.gov

11. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Tennessee Oncology, PLLC, Nashville, Tennessee

    Locations

    243 in total

    Run by

    Relay Therapeutics, Inc.

    See if you can join NCT06982521 on ClinicalTrials.gov

12. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Sarah Cannon Research Institute, Nashville, Tennessee

    Locations

    76 in total

    Run by

    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

13. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Nashville, Tennessee

    Locations

    20 in total

    Run by

    AstraZeneca

    See if you can join NCT05877599 on ClinicalTrials.gov

14. IKS014 in Advanced Solid Tumors That Express HER2

    This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Tennessee Oncology, Nashville, Tennessee

    Locations

    13 in total

    Run by

    Iksuda Therapeutics Ltd.

    See if you can join NCT05872295 on ClinicalTrials.gov

15. A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

    This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inop…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Research Site, Nashville, Tennessee

    Locations

    318 in total

    Run by

    AstraZeneca

    See if you can join NCT06103864 on ClinicalTrials.gov

16. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

    This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Clinical Trial Site, Nashville, Tennessee

    Locations

    200 in total

    Run by

    Olema Pharmaceuticals, Inc.

    See if you can join NCT07085767 on ClinicalTrials.gov

17. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    SCRI Oncology Partners, Nashville, Tennessee

    Locations

    567 in total

    Run by

    Stemline Therapeutics, Inc.

    See if you can join NCT06492616 on ClinicalTrials.gov

18. Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

    Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn: * About the safety of the study treatments and if people toler…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    SCRI Oncology Partners ( Site 7000), Nashville, Tennessee

    Locations

    17 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06797635 on ClinicalTrials.gov

19. A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

    AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Center, Nashville, Tennessee

    Locations

    7 in total

    Run by

    Angiex, Inc.

    See if you can join NCT06440005 on ClinicalTrials.gov

20. Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

    For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later. A way to find these cells is by looking for tiny bits of cancer DNA that are …

    Stage

    Not phased

    Ages

    18 to 99

    Site

    Nashville General, Nashville, Tennessee

    Locations

    16 in total

    Run by

    Tempus AI

    See if you can join NCT07211178 on ClinicalTrials.gov

21. A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

    A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.

    Stage

    Phase 1

    Ages

    21 and older

    Site

    Sarah Cannon Research Institute/SCRI, Nashville, Tennessee

    Locations

    4 in total

    Run by

    MBQ Pharma

    See if you can join NCT06075810 on ClinicalTrials.gov

22. TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

    The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HE…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Vanderbilt Cancer Center, Nashville, Tennessee

    Locations

    11 in total

    Run by

    Ana C Garrido-Castro, MD

    See if you can join NCT06533826 on ClinicalTrials.gov

23. Collecting and Storing Tissue Samples From Women With or Without Breast Cancer

    RATIONALE: Collecting and storing samples of tissue, blood, and urine from patients with or without breast cancer to study in the laboratory may help the study of cancer. PURPOSE: This research study is collecting and storing tissue samples from women with or without breast cancer.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

    Run by

    Vanderbilt-Ingram Cancer Center

    See if you can join NCT00899301 on ClinicalTrials.gov

24. ATEMPT 2.0: Adjuvant T-DM1 vs TH

    This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Greco-Hainsworth Centers for Research/Tennessee Oncology, Nashville, Tennessee

    Locations

    53 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04893109 on ClinicalTrials.gov

25. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of car…

    Stage

    Phase 3

    Ages

    18 to 100

    Site

    SCRI Oncology Partners, Nashville, Tennessee

    Locations

    179 in total

    Run by

    Greenwich LifeSciences, Inc.

    See if you can join NCT05232916 on ClinicalTrials.gov